CA2594456C - System and method for prediction of adverse events during treatment of psychological and neurological disorders - Google Patents
System and method for prediction of adverse events during treatment of psychological and neurological disorders Download PDFInfo
- Publication number
- CA2594456C CA2594456C CA2594456A CA2594456A CA2594456C CA 2594456 C CA2594456 C CA 2594456C CA 2594456 A CA2594456 A CA 2594456A CA 2594456 A CA2594456 A CA 2594456A CA 2594456 C CA2594456 C CA 2594456C
- Authority
- CA
- Canada
- Prior art keywords
- feature
- psychological
- adverse event
- predicting
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
- A61B5/374—Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
Abstract
The present invention is a system and method of deriving and computing features and indices that predict the likelihood of psychological and neurological adverse events such as suicidal thoughts and/or actions. The method of the present invention further predicts the likelihood of suicidal thoughts and/or actions prior to and/or during treatment for psychological disease. To obtain such features and indices, power spectrum and time domain values are derived from biopotential signals acquired from the subject being tested. The system and method identify people who are likely to experience changing, especially worsening, symptoms of psychological and neurological adverse events such as suicidal thoughts or actions and who therefore may be at risk (e.g. suicide).
Description
SYSTEM AND METHOD FOR PREDICTION
OF ADVERSE EVENTS DURING TREATMENT
OF PSYCHOLOGICAL AND NEUROLOGICAL DISORDERS
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from United States Provisional Application Serial No.
60/643,350 filed on January 12, 2005.
BACKGROUND
OF ADVERSE EVENTS DURING TREATMENT
OF PSYCHOLOGICAL AND NEUROLOGICAL DISORDERS
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from United States Provisional Application Serial No.
60/643,350 filed on January 12, 2005.
BACKGROUND
[0002] Depression is a mood disorder that affects 17 million Americans each year, and is responsible for 9.7 million doctor visits. It affects sufferers in a variety of ways, resulting in depressed mood, irritability, sleep disorders, feelings of agitation, guilt and worthlessness, loss of energy and initiative, an inability to concentrate and an increased incidence of suicide.
There are a number of antidepressant pharmacological agents, and once the proper treatment is determined, their effectiveness is quite high.
There are a number of antidepressant pharmacological agents, and once the proper treatment is determined, their effectiveness is quite high.
[0003] Major Depressive Disorder (MDD) is the psychiatric diagnosis most commonly associated with completed suicide. The American Association of Suicidology notes on their website that the lifetime risk of suicide among patients with untreated MDD is nearly 20%.
About 2/3 of people who complete suicide are depressed at the time of their deaths. In a study conducted in Finland, of 71 individuals who completed suicide and who had Major Depressive Disorder, only 45% were receiving treatment at the time of death and only a third of these were taking antidepressants.
About 2/3 of people who complete suicide are depressed at the time of their deaths. In a study conducted in Finland, of 71 individuals who completed suicide and who had Major Depressive Disorder, only 45% were receiving treatment at the time of death and only a third of these were taking antidepressants.
[0004] Evidence suggests that pharmacological treatment of some depressed subjects may increase the risk of suicidal thinking and behavior in adolescents.
Development of methods to identify those subjects who are at increased risk of developing adverse events, especially suicide, would provide significant benefit to both patients and clinicians.
= CA 02594456 2013-10-15 '=
Development of methods to identify those subjects who are at increased risk of developing adverse events, especially suicide, would provide significant benefit to both patients and clinicians.
= CA 02594456 2013-10-15 '=
[0005] Cook et al.. demonstrated that pre-frontal electroencephalographic (EbG) cordance, a quantitative EEG (QEEG) parameter, predicts successful response to fluoxetine antidepressant therapy. Greenwald et al. in United Stnte-s Patent Application Serial No.:
10/337,088 described the use of EEG indices using bispectral features to assess the severity of depression and to predict response to antidepressant pharmacological treatment. It has been reported that side effect burden, characterized as the mean number of side effects per clinical visit, correlated with changes in an EEG index (prefrontal cordance) during the placebo lead-in period in patients receiving antidepressant treatment, but not in a placebo control group.
10/337,088 described the use of EEG indices using bispectral features to assess the severity of depression and to predict response to antidepressant pharmacological treatment. It has been reported that side effect burden, characterized as the mean number of side effects per clinical visit, correlated with changes in an EEG index (prefrontal cordance) during the placebo lead-in period in patients receiving antidepressant treatment, but not in a placebo control group.
[0006] Others have observed that abnormal electroencephalographic (EEG) activity has been associated with various psychiatric disorders and behaviors, including depression, suicide, and aggression and reported that differences in the intrahemispheric distribution of EEG
alpha band power (alpha asymmetry), particularly over posterior regions of the scalp, differed between adolescent female suicide attempters and matched controls.
Specifically, the controls exhibited greater BEG alpha band power over right than left hemispheres as compared to suicide attempters. Note that this study was not a prediction of the risk of suicidal behavior, but an observational study of EEG patterns conducted subsequent to suicide attempts. Several researchers have reported that paroxysmal EEG
abnormalities increase the risk of suicide in patients.
SUMMARY OF THE INVENTION
alpha band power (alpha asymmetry), particularly over posterior regions of the scalp, differed between adolescent female suicide attempters and matched controls.
Specifically, the controls exhibited greater BEG alpha band power over right than left hemispheres as compared to suicide attempters. Note that this study was not a prediction of the risk of suicidal behavior, but an observational study of EEG patterns conducted subsequent to suicide attempts. Several researchers have reported that paroxysmal EEG
abnormalities increase the risk of suicide in patients.
SUMMARY OF THE INVENTION
[0007] Some embodiments of the present invention are directed to a system and method of deriving and computing features and indices that predict the likelihood of psychological and neurological adverse events such a suicidal thoughts and/or actions. The method of some embodiments of the present invention further predicts the likelihood of suicidal thoughts and/or actions prior to and or during treatment for psychological disease. To obtain such features and indices, power spectrum and time domain values are derived from biopotential signals acquired from the subject being tested. The system and method identify people who are likely to experience changing; especially worsening symptoms of psychological and neurological adverse events such as suicidal thought or actions and who therefore may be at risk (e.g.
suicide).
=
[0007a] According to one aspect of the present invention, there is provided a system for predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals comprising: a data acquisition unit for acquiring electroencephalographic signals from a subject being evaluated, a processor for: computing at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of the subject, creating an index by combining said first feature and said second feature, and predicting the adverse event through the use of said index, wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
[0007b] According to another aspect of the present invention, there is provided a method of predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals, comprising the steps of: acquiring electroencephalographic signals from a subject being evaluated, computing with a processor at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of said subject, creating an index by combining said first feature and said second feature, predicting the psychological and neurological adverse event through the use of said index, and wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
2a BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 is a block diagram of the system of the present invention for predicting adverse events during treatment of psychological and neurological disorders.
suicide).
=
[0007a] According to one aspect of the present invention, there is provided a system for predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals comprising: a data acquisition unit for acquiring electroencephalographic signals from a subject being evaluated, a processor for: computing at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of the subject, creating an index by combining said first feature and said second feature, and predicting the adverse event through the use of said index, wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
[0007b] According to another aspect of the present invention, there is provided a method of predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals, comprising the steps of: acquiring electroencephalographic signals from a subject being evaluated, computing with a processor at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of said subject, creating an index by combining said first feature and said second feature, predicting the psychological and neurological adverse event through the use of said index, and wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
2a BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 is a block diagram of the system of the present invention for predicting adverse events during treatment of psychological and neurological disorders.
[0009] Figure 2 is a flow chart of the steps of the method of the present invention.
[0010] Figure 3 is an error bar chart showing the values of the Index Pred2 for the Worsening Suicide Ideation (Si) and Not Worsening SI groups, stratified by antidepressant treatment.
[0011] Figure 4 is an error bar chart showing the value of Pred2 vs. the maximum change from baseline observed in Ham-D item 3 during the first four weeks of treatment.
[0012] Figure 5 is an error bar chart showing the baseline value of the left-minus-right relative theta+alpha asymmetry feature (BDRTAS12) for the Worsening SI and Not Worsening SI groups, stratified by antidepressant treatment.
[0013] Figure 6 is a scatter plot of left-minus-right relative theta+alpha asymmetry measured at baseline (BDRTAS12) and at 1 week (DRTAS12).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Referring to Figures 1 and 2, a preferred embodiment of the present invention shown in Figure 1 incorporates a Data Acquisition Unit (DAU) 20 that is used to acquire an EEG
signal in step 22 from a subject 10 for subsequent processing. The DAU 20 typically consists of a computer system with an integral analog-to-digital (A-D) converter 25 and a set of electrodes that is representatively shown placed on the scalp of a subject 10.
While only a single electrode 15 is shown, any montage of electrodes used to obtain EEG
signals may be used in the invention. The A-D converter 25 is used to transform in step 24 the analog EEG
signals obtained from the electrodes 15 into a sampled set of signal values that may then be analyzed by the processor 35 of a Data Computation Unit (DCU) 30. The DCU 30 incorporates a processor 35 and a communications device that receives the sampled values from the DAU 20. In the preferred embodiment, the processors of the DAU 20 and are one and the same. In an alternate embodiment, however, the DAU 20 may acquire the EEG signals and transmit the sampled EEG signals over a communications link to a remote DCU 30. Such a communications link may be a serial or parallel data line, a local or wide area network, a telephone line, the Internet, or a wireless connection. The clinician conducting the assessment may communicate with the DCU 30 using a keyboard 40 and display device 50. In the alternate embodiment that utilizes a DCU 30 remote from the DAU
20, an additional keyboard and display device may be attached to the DAU 20 for the use of the clinician.
signal in step 22 from a subject 10 for subsequent processing. The DAU 20 typically consists of a computer system with an integral analog-to-digital (A-D) converter 25 and a set of electrodes that is representatively shown placed on the scalp of a subject 10.
While only a single electrode 15 is shown, any montage of electrodes used to obtain EEG
signals may be used in the invention. The A-D converter 25 is used to transform in step 24 the analog EEG
signals obtained from the electrodes 15 into a sampled set of signal values that may then be analyzed by the processor 35 of a Data Computation Unit (DCU) 30. The DCU 30 incorporates a processor 35 and a communications device that receives the sampled values from the DAU 20. In the preferred embodiment, the processors of the DAU 20 and are one and the same. In an alternate embodiment, however, the DAU 20 may acquire the EEG signals and transmit the sampled EEG signals over a communications link to a remote DCU 30. Such a communications link may be a serial or parallel data line, a local or wide area network, a telephone line, the Internet, or a wireless connection. The clinician conducting the assessment may communicate with the DCU 30 using a keyboard 40 and display device 50. In the alternate embodiment that utilizes a DCU 30 remote from the DAU
20, an additional keyboard and display device may be attached to the DAU 20 for the use of the clinician.
[0015] After the DCU 30 receives the sampled values from the DAU 20, the DCU
30 first examines in step 26 the sampled EEG signals for artifact arising from patient movement, eye blinks, electrical noise, etc. Detected artifact is either removed from the signal, or the portion of the signal with artifact is excluded from further processing. The EEG
signal is also filtered to reduce or remove artifact from high and/or low frequency noise sources, such as electromyographic and radio frequency interference and movement artifact, respectively.
Low-pass filtering is also employed prior to sampling to reduce the power at frequencies above the signal band of interest, preventing that power from appearing artifactually at lower frequencies due to an inadequate sampling frequency (aliasing).
30 first examines in step 26 the sampled EEG signals for artifact arising from patient movement, eye blinks, electrical noise, etc. Detected artifact is either removed from the signal, or the portion of the signal with artifact is excluded from further processing. The EEG
signal is also filtered to reduce or remove artifact from high and/or low frequency noise sources, such as electromyographic and radio frequency interference and movement artifact, respectively.
Low-pass filtering is also employed prior to sampling to reduce the power at frequencies above the signal band of interest, preventing that power from appearing artifactually at lower frequencies due to an inadequate sampling frequency (aliasing).
[0016] The DCU 30 next computes a set of parameters from the artifact-free EEG
data in step 28. Parameters may be derived from power spectral arrays, higher-order spectral arrays (bispectrum, trispectrum, etc.), cordance (such as described in U.S. Pat. No.
5,269,315 and U.S. Pat. No. 5,309,923), z-transformed variables, entropy metrics, and time-domain metrics, including but not limited to parameters derived from various techniques applied to the various data series, such as template matching, peak detection, threshold crossing, zero crossings and Hjorth descriptors. Such parameters, which quantify some aspect of the data, are referred to as features. Features may also be formed from combinations of parameters.
An index is a function incorporating one or more features as variables. The index function may be linear or nonlinear, or may have an alternative form such as a neural network. In step 32, the DCU 30 calculates from all the parameters a series of features and indices that are predictive of the probability the subject may experience adverse events, such as suicide ideation or suicidal actions. These features and indices may be displayed to the user on the display device 50 in step 34. In the embodiment in which the DCU 30 is remote from the DAU 20, the result may be transmitted back to the display device on the DAU
20, or transmitted to the patient's physician via e-mail or made available via a secure internet World Wide Web page.
data in step 28. Parameters may be derived from power spectral arrays, higher-order spectral arrays (bispectrum, trispectrum, etc.), cordance (such as described in U.S. Pat. No.
5,269,315 and U.S. Pat. No. 5,309,923), z-transformed variables, entropy metrics, and time-domain metrics, including but not limited to parameters derived from various techniques applied to the various data series, such as template matching, peak detection, threshold crossing, zero crossings and Hjorth descriptors. Such parameters, which quantify some aspect of the data, are referred to as features. Features may also be formed from combinations of parameters.
An index is a function incorporating one or more features as variables. The index function may be linear or nonlinear, or may have an alternative form such as a neural network. In step 32, the DCU 30 calculates from all the parameters a series of features and indices that are predictive of the probability the subject may experience adverse events, such as suicide ideation or suicidal actions. These features and indices may be displayed to the user on the display device 50 in step 34. In the embodiment in which the DCU 30 is remote from the DAU 20, the result may be transmitted back to the display device on the DAU
20, or transmitted to the patient's physician via e-mail or made available via a secure internet World Wide Web page.
[0017] In the preferred embodiment, the EEG data is collected using Ag-AgC1 electrodes of the type sold by Grass-Telefactor of Warwick, Rhode Island under the designation Model F-E5SHC. A bipolar 4-channel electrode montage is preferentially utilized, with each EEG
channel collected as the voltage difference between each of the four pairs of electrodes F7-Fpz, F8-Fpz, Al-Fpz and A2-Fpz (International Ten-Twenty System of Electrode Placement, Jasper) where Al is the left earlobe and A2 is the right earlobe. When the electrodes are all to be placed below the hairline, the electrodes are preferably of the Zipprep type manufactured by Aspect Medical Systems, Inc. of Newton, Massachusetts or other such Ag-AgC1 electrodes, such as those manufactured by Grass-Telefactor, Inc. When electrodes are placed within the hair, gold-cup type electrodes may be used, held in place by either collodion or a physical restraint such as an electrode cap placement device, as provided by various manufacturers. A variety of different electrode placements, or montages, may be used.
channel collected as the voltage difference between each of the four pairs of electrodes F7-Fpz, F8-Fpz, Al-Fpz and A2-Fpz (International Ten-Twenty System of Electrode Placement, Jasper) where Al is the left earlobe and A2 is the right earlobe. When the electrodes are all to be placed below the hairline, the electrodes are preferably of the Zipprep type manufactured by Aspect Medical Systems, Inc. of Newton, Massachusetts or other such Ag-AgC1 electrodes, such as those manufactured by Grass-Telefactor, Inc. When electrodes are placed within the hair, gold-cup type electrodes may be used, held in place by either collodion or a physical restraint such as an electrode cap placement device, as provided by various manufacturers. A variety of different electrode placements, or montages, may be used.
[0018] In the preferred embodiment, EEG signals are sampled by the A-D
converter 25 at 128 samples-per-second, preferably while the subject's eyes are closed in order to minimize eye-blink artifacts. The sampled EEG signal from each electrode pair is processed independently; the initial processing will be described for a single channel, but it should be understood that it is identical for each channel. The sampled EEG signal is divided into non-overlapping, 2-second epochs. In the preferred embodiment, 4 minutes of EEG
data is processed, consisting of 120 non-overlapping, consecutive, 2-second epochs.
For each 2-second epoch, a power spectrum (at 0.5 Hz resolution) is calculated using a Fast Fourier Transform (FFT) after first mean de-trending to remove the DC (offset) component of the signal and then minimizing spectral leakage (smearing) by multiplying the epoch with a Hamming window. The median power spectrum of the 120 epochs is calculated by computing the median of the corresponding frequency values of the power spectra associated with each of the 120 epochs. Absolute and relative powers are calculated from the median power spectrum for a set of predefined frequency bands; these are the theta (4-7.5 Hz), alpha (8-11.5 Hz), theta+alpha (4-11.5 Hz) and total power (2-20 Hz) frequency bands. The absolute power is calculated as the sum of the power within each specific frequency band in the median power spectrum, and the relative power is calculated as the ratio of the absolute power of a specific frequency band to the absolute power of the total power frequency band.
Various absolute and relative powers as well as combinations, products and ratios of absolute and relative powers within and among the EEG channels are combined to form a pool of candidate features.
converter 25 at 128 samples-per-second, preferably while the subject's eyes are closed in order to minimize eye-blink artifacts. The sampled EEG signal from each electrode pair is processed independently; the initial processing will be described for a single channel, but it should be understood that it is identical for each channel. The sampled EEG signal is divided into non-overlapping, 2-second epochs. In the preferred embodiment, 4 minutes of EEG
data is processed, consisting of 120 non-overlapping, consecutive, 2-second epochs.
For each 2-second epoch, a power spectrum (at 0.5 Hz resolution) is calculated using a Fast Fourier Transform (FFT) after first mean de-trending to remove the DC (offset) component of the signal and then minimizing spectral leakage (smearing) by multiplying the epoch with a Hamming window. The median power spectrum of the 120 epochs is calculated by computing the median of the corresponding frequency values of the power spectra associated with each of the 120 epochs. Absolute and relative powers are calculated from the median power spectrum for a set of predefined frequency bands; these are the theta (4-7.5 Hz), alpha (8-11.5 Hz), theta+alpha (4-11.5 Hz) and total power (2-20 Hz) frequency bands. The absolute power is calculated as the sum of the power within each specific frequency band in the median power spectrum, and the relative power is calculated as the ratio of the absolute power of a specific frequency band to the absolute power of the total power frequency band.
Various absolute and relative powers as well as combinations, products and ratios of absolute and relative powers within and among the EEG channels are combined to form a pool of candidate features.
[0019] It would be obvious to those skilled in the art that the pool of candidate features could be extended beyond power spectral features to include features derived from other methods of representing EEG information, including, but not limited to, bispectral analysis, time-frequency analyses, entropy metrics, fractal metrics, correlation dimension, as well as cross-channel analyses including coherence, cross-spectra, cross-bispectral features and mutual information metrics.
[0020] In the preferred embodiment, a set of EEG features are combined to form an index whose value is predictive of the probability that the subject will respond to antidepressant treatment. The mathematical structure of the index, the variables and the coefficients used and their method of combination were developed using a statistical modeling technique.
[0021] Following Institutional Review Board approval and written informed consent, 36 outpatients meeting DSM-W (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) criteria for Major Depressive Disorder (MDD) entered an 8-week prospective treatment trial with open-label, flexible dose selective serotonin reuptake inhibitor (SSRI) antidepressants. The 17-item Hamilton Depression Rating Scale (Hain-D) was administered at unmedicated baseline and at weeks 1, 4 and 8 during treatment to assess changes in depressive symptoms. Treatment response as defined as a reduction of the Ham-D
score at week 8 of at least 50% from baseline. At each study visit (baseline, weeks 1, 4 and 8) serial, 4-channel EEGs were sampled at 128 samples-per-second, and recorded to computer using an Aspect A1000 EEG Monitor sold by Aspect Medical Systems of Newton, Massachusetts).
As described above, a pool of candidate EEG features were extracted from each recording.
score at week 8 of at least 50% from baseline. At each study visit (baseline, weeks 1, 4 and 8) serial, 4-channel EEGs were sampled at 128 samples-per-second, and recorded to computer using an Aspect A1000 EEG Monitor sold by Aspect Medical Systems of Newton, Massachusetts).
As described above, a pool of candidate EEG features were extracted from each recording.
[0022] Using the binary treatment response as the dependent variable, logistic regression was used to identify those candidate EEG features measured at baseline and week 1 which were, when combined in a model, predictive of response to treatment. The resultant logistic model predicted the probability of response to treatment ("Pred2", scaled 0 to 100%):
''Pr ed2 =100 1+e 23355(1 BMRT12 MRTI2one ...t,õk )+39.0795.MRT78one _ õõk +14.6946.BDRTAS 12-9.0977 where:
MRT12 is the mean of the relative theta powers calculated on channels Al-Fpz and A2-Fpz, MRT120.e_week - is the value of MRT12 measured at one week, BMRT12 is the value of MRT12 measured at baseline, MRT78 is the mean of the relative theta powers calculated on channels F7-Fpz and F8-Fpz, MRT780.e_week ..s i the value of MRT78 measured at one week, DRTAS12 is the value of the combined relative theta+alpha power on channel A 1-Fpz minus the combined relative theta+alpha power on channel A2-Fpz (DRTAS12 is therefore a measure of left-minus-right asymmetry), DRTAS120.eweek _s _ i the value of DRTAS12 measured at one week and BDRTAS12 is the value of DRTAS12 measured at baseline.
''Pr ed2 =100 1+e 23355(1 BMRT12 MRTI2one ...t,õk )+39.0795.MRT78one _ õõk +14.6946.BDRTAS 12-9.0977 where:
MRT12 is the mean of the relative theta powers calculated on channels Al-Fpz and A2-Fpz, MRT120.e_week - is the value of MRT12 measured at one week, BMRT12 is the value of MRT12 measured at baseline, MRT78 is the mean of the relative theta powers calculated on channels F7-Fpz and F8-Fpz, MRT780.e_week ..s i the value of MRT78 measured at one week, DRTAS12 is the value of the combined relative theta+alpha power on channel A 1-Fpz minus the combined relative theta+alpha power on channel A2-Fpz (DRTAS12 is therefore a measure of left-minus-right asymmetry), DRTAS120.eweek _s _ i the value of DRTAS12 measured at one week and BDRTAS12 is the value of DRTAS12 measured at baseline.
[0023] In the preferred embodiment, the structure of the index Pred2 and its components were further refined to form an index whose value is predictive of the probability of the subject suffering an adverse event. In the preferred embodiment, the adverse event is the ideation of suicide (e.g., the occurrence of suicidal thoughts or actions, as quantified by a neurocognitive assessment scale).
[0024] In order to evaluate the ability of the Pred2 Index to predict suicide ideation, following model development additional subjects were added to the database for a total of 42 subjects. Item 3 of the Hamilton Depression Rating Scale was examined for each subject to identify those individuals who developed new (or worsening) symptoms of suicide ideation.
Pred2 and its components were evaluated to determine if they could predict which subjects would have new or worsening symptoms of suicide ideation. These variables were also evaluated to determine if they correlated with change in severity of symptoms of suicide ideation from baseline.
Pred2 and its components were evaluated to determine if they could predict which subjects would have new or worsening symptoms of suicide ideation. These variables were also evaluated to determine if they correlated with change in severity of symptoms of suicide ideation from baseline.
[0025] A binary-valued variable (SuicideGroup) was calculated for each subject to indicate whether the subject developed new or worsening symptoms of suicide ideation (WorseSI) or not (NotWorseSI) at visits at 1 and 4 weeks. Analysis of variance of Pred2, controlling for the antidepressant treatment the patient later received (i.e., escitalopram, fluoxetine or venlafaxine), demonstrated that the values of Pred2 were significantly different between the WorseSI and NotWorseSI groups (p=0.005) when accounting for differences among treatment groups (Figure 3 The horizontal line across the inside of the box is the median value of the data points in each subgroup, while the upper and lower box edges are the 75th and 25th percentiles, respectively, and thus the box length is the interquartile range. The horizontal lines at the end of the "whiskers" above and below the boxes represent the most extreme values of the data points in each subgroup). Pred2 also correlated with maximal worsening of suicide ideation (Si) within the first four weeks of treatment (Spearman rank correlation (R) = -0.307, p=0.047) as shown in Figure 4. In addition, the baseline left-minus-right relative theta+alpha asymmetry feature (BDRTAS12) was borderline significantly different between the WorseSI and NotWorseSI groups (p=0.053). Subjects who developed new suicide ideation (SI) symptoms generally had positive (i.e., left-dominant) asymmetry.
The feature BDRTAS12 seems to perform similarly regardless of which antidepressant treatment the patient later receives (Figure 5).
The feature BDRTAS12 seems to perform similarly regardless of which antidepressant treatment the patient later receives (Figure 5).
[0026] The use of baseline relative theta+alpha asymmetry (BDRTAS12) as a predictor of future development of SI symptoms achieved the following performance in this dataset: 67%
sensitivity, 78% specificity and 76% accuracy, with 33% positive predictive accuracy (PPA) and 93% negative predictive accuracy (NPA). Relative theta+alpha asymmetry (DRTAS12one week) measured at week 1 provides additional information that improves discrimination of subjects who do (and don't) develop SI symptoms (Figure 6).
EEG
asymmetry in subjects who developed new SI symptoms initially was >0 at baseline, and did not significantly decrease after 1 week of treatment. Using a detection rule that classifies subjects having both BDRTAS12 >0 and DRTAS120ne_week > -0.02 as being likely to develop SI symptoms and the remaining subjects as being not likely to develop SI
symptoms achieved the following performance in this dataset: 67% sensitivity, 89% specificity and 86%
accuracy, with 50% PPA and 94% NPA.
sensitivity, 78% specificity and 76% accuracy, with 33% positive predictive accuracy (PPA) and 93% negative predictive accuracy (NPA). Relative theta+alpha asymmetry (DRTAS12one week) measured at week 1 provides additional information that improves discrimination of subjects who do (and don't) develop SI symptoms (Figure 6).
EEG
asymmetry in subjects who developed new SI symptoms initially was >0 at baseline, and did not significantly decrease after 1 week of treatment. Using a detection rule that classifies subjects having both BDRTAS12 >0 and DRTAS120ne_week > -0.02 as being likely to develop SI symptoms and the remaining subjects as being not likely to develop SI
symptoms achieved the following performance in this dataset: 67% sensitivity, 89% specificity and 86%
accuracy, with 50% PPA and 94% NPA.
[0027] FIG. 5 shows that the distance from the origin (0,0) of the DRTAS1200e_week vs.
BDRTAS12 relationship is a predictor of the probability of suicide ideation in a specific individual. All those patients who experienced suicide ideation were tightly clustered at the center of the DRTAS120ne_ week vs. BDRTAS12 scatter plot. Among those patients corresponding to data points far from the origin there were no instances of suicide ideation.
Therefore, an alternate embodiment of the invention is derived from the sum of the absolute values of DRTAS1 2one_week and BDRTAS12.
IrideXsuicidejdeation 1DRTAS1 20ne_week 1 + I BDRTAS12 A very low risk of suicide ideation is associated with values of Indexsuicide_ideation > 0.06. In an alternate embodiment, a mathematically intuitive measure of the risk of suicide ideation may be constructed as the distance of a data point from the origin of the scatter plot in FIG. 5, computed as Indexsuicide_ideation2 = (I DRTAS 1 2one week 12 + I BDRTAS12 12 )112 Increasing distances from the origin, expressed as increasing values of Indexsuicide jcleation2, are predictive of a decreasing probability of suicide ideation.
BDRTAS12 relationship is a predictor of the probability of suicide ideation in a specific individual. All those patients who experienced suicide ideation were tightly clustered at the center of the DRTAS120ne_ week vs. BDRTAS12 scatter plot. Among those patients corresponding to data points far from the origin there were no instances of suicide ideation.
Therefore, an alternate embodiment of the invention is derived from the sum of the absolute values of DRTAS1 2one_week and BDRTAS12.
IrideXsuicidejdeation 1DRTAS1 20ne_week 1 + I BDRTAS12 A very low risk of suicide ideation is associated with values of Indexsuicide_ideation > 0.06. In an alternate embodiment, a mathematically intuitive measure of the risk of suicide ideation may be constructed as the distance of a data point from the origin of the scatter plot in FIG. 5, computed as Indexsuicide_ideation2 = (I DRTAS 1 2one week 12 + I BDRTAS12 12 )112 Increasing distances from the origin, expressed as increasing values of Indexsuicide jcleation2, are predictive of a decreasing probability of suicide ideation.
[0028] The EEG Pred2 index and the EEG asymmetry features DRTAS12õ,,õk and BDRTAS12 are useful predictors of response to treatment and probability of adverse events, especially suicide ideation. Change in these metrics in response to initial treatment may provide additional information that might improve prediction performance.
Although these metrics were developed to predict responses related to pharmacological treatment, it is anticipated that they may predict response to other forms of treatment, including, but not limited to, psychotherapy, electroconvulsive therapy (ECT), transmagnetic stimulation and various forms of neurostimulation including deep brain stimulation and peripheral nerve stimulation (e.g., vagus nerve stimulation).
Although these metrics were developed to predict responses related to pharmacological treatment, it is anticipated that they may predict response to other forms of treatment, including, but not limited to, psychotherapy, electroconvulsive therapy (ECT), transmagnetic stimulation and various forms of neurostimulation including deep brain stimulation and peripheral nerve stimulation (e.g., vagus nerve stimulation).
[0029] Although the indices (metrics) of the preferred embodiment were developed to predict responses and events related to treatment of depression, it is anticipated that these metrics may predict response and/or adverse events when treating other types of psychological and neurological disorders, including, but not limited to, anxiety, bipolar depression, mania, schizophrenia, obsessive-compulsive disorder and dementia.
[0030] The above study demonstrated that the EEG Pred2 index, the EEG
asymmetry features DRTAS120ne_week and BDRTAS12, and the indices Indexsuidde ideation and Indexsuicide_ideation2, may be used to predict onset of adverse symptoms, including changes in suicide ideation and suicidal actions. These indices, as well as other EEG-based indices, hereafter referred to as EEG Index, may also be used prior to treatment to predict eventual onset of symptoms due to treatment.
asymmetry features DRTAS120ne_week and BDRTAS12, and the indices Indexsuidde ideation and Indexsuicide_ideation2, may be used to predict onset of adverse symptoms, including changes in suicide ideation and suicidal actions. These indices, as well as other EEG-based indices, hereafter referred to as EEG Index, may also be used prior to treatment to predict eventual onset of symptoms due to treatment.
[0031] The EEG Index may be computed and used to predict the onset of adverse symptoms throughout the course of therapy.
[0032] The EEG Index may be used to predict other adverse symptoms such as somatie symptoms, sexual side-effects, nausea, vomiting and other symptoms not considered to be manifestations of improvement of the psychological and/or neurological condition.
[0033] While the foregoing invention has been described with reference to its preferred embodiments, various alterations and modifications will occur to these skilled in the art. All such alterations and modifications are intended to fall within the scope of the appended claims.
Claims (10)
1. A system for predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals comprising:
a data acquisition unit for acquiring electroencephalographic signals from a subject being evaluated, a processor for:
computing at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of the subject, creating an index by combining said first feature and said second feature, and predicting the adverse event through the use of said index, wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
a data acquisition unit for acquiring electroencephalographic signals from a subject being evaluated, a processor for:
computing at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of the subject, creating an index by combining said first feature and said second feature, and predicting the adverse event through the use of said index, wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
2. The system for predicting a psychological and neurological adverse event from electroencephalographic signals of claim 1, wherein said index combining said first and second features is a distance from an origin to a point represented by said first and second features.
3. The system for predicting a psychological and neurological adverse event from electroencephalographic signals of claim 1 wherein said at least one parameter is computed using a combination of relative EEG theta power and relative combined theta +
alpha asymmetry.
alpha asymmetry.
4. The system for predicting a psychological and neurological adverse event from electroencephalographic signals of claim 1, wherein said first feature and said second feature are relative theta frequency band power.
5. The system for predicting a psychological and neurological adverse event from electroencephalographic signals of claim 1, wherein said first feature and said second feature are relative theta + alpha frequency band asymmetry.
6. A method of predicting a psychological and neurological adverse event from electroencephalographic (EEG) signals, comprising the steps of:
acquiring electroencephalographic signals from a subject being evaluated, computing with a processor at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of said subject, creating an index by combining said first feature and said second feature, predicting the psychological and neurological adverse event through the use of said index, and wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
acquiring electroencephalographic signals from a subject being evaluated, computing with a processor at least one parameter from said electroencephalographic signals, deriving a first feature from said at least one parameter at a pre-treatment condition, deriving a second feature from said at least one parameter after an initiation of treatment of said subject, creating an index by combining said first feature and said second feature, predicting the psychological and neurological adverse event through the use of said index, and wherein said treatment is pharmacological treatment, psychotherapy, electroconvulsive therapy, transmagnetic stimulation or neurostimulation and wherein said adverse event is suicidal thoughts, suicidal actions, somatic symptoms, sexual side-effects, nausea or vomiting.
7. The method of predicting a psychological and neurological adverse event from electroencephalographic signals of claim 6, wherein said first feature and said second feature are relative theta frequency band power.
8. The method of predicting a psychological and neurological adverse event from electroencephalographic signals of claim 6, wherein said first feature and said second feature are relative theta + alpha frequency band asymmetry.
9. The method of predicting a psychological and neurological adverse event from electroencephalographic signals of claim 6, wherein said index combining said first and second features is a distance from an origin to a point represented by said first and second features.
10. The method of predicting a psychological and neurological adverse event from electroencephalographic signals of claim 6 wherein said at least one parameter is computed using a combination of relative EEG theta power and relative combined theta +
alpha asymmetry.
alpha asymmetry.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64335005P | 2005-01-12 | 2005-01-12 | |
| US60/643,350 | 2005-01-12 | ||
| PCT/US2006/001059 WO2006076478A2 (en) | 2005-01-12 | 2006-01-12 | System and method for prediction of adverse events during treatment of psychological and neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2594456A1 CA2594456A1 (en) | 2006-07-20 |
| CA2594456C true CA2594456C (en) | 2014-04-29 |
Family
ID=36406578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2594456A Expired - Fee Related CA2594456C (en) | 2005-01-12 | 2006-01-12 | System and method for prediction of adverse events during treatment of psychological and neurological disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8005534B2 (en) |
| EP (1) | EP1856643A1 (en) |
| JP (1) | JP2008526388A (en) |
| CN (1) | CN101529429A (en) |
| AU (1) | AU2006204963B2 (en) |
| BR (1) | BRPI0606306A2 (en) |
| CA (1) | CA2594456C (en) |
| MX (1) | MX2007008439A (en) |
| WO (1) | WO2006076478A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
| US8521270B2 (en) * | 2006-06-05 | 2013-08-27 | The Regents Of The University Of California | Quantitative EEG method to identify individuals at risk for adverse antidepressant effects |
| BRPI0812854B8 (en) * | 2007-06-22 | 2021-06-22 | Cmte Dev Ltd | scalp voltage potential measuring apparatus and method |
| US20100114237A1 (en) * | 2008-10-31 | 2010-05-06 | Medtronic, Inc. | Mood circuit monitoring to control therapy delivery |
| US20100292545A1 (en) * | 2009-05-14 | 2010-11-18 | Advanced Brain Monitoring, Inc. | Interactive psychophysiological profiler method and system |
| EP2621333B1 (en) | 2010-09-28 | 2015-07-29 | Masimo Corporation | Depth of consciousness monitor including oximeter |
| US20140258306A1 (en) * | 2011-10-12 | 2014-09-11 | The Johns Hopkins University | Novel Simulation and Permutation Methods for the Determination of Temporal Association between Two Events |
| CN102715903B (en) * | 2012-07-09 | 2014-04-16 | 天津市人民医院 | Method for extracting electroencephalogram characteristic based on quantitative electroencephalogram |
| CN104902806B (en) * | 2012-11-10 | 2019-06-04 | 加利福尼亚大学董事会 | The assessment system and method for europathology |
| US9526437B2 (en) | 2012-11-21 | 2016-12-27 | i4c Innovations Inc. | Animal health and wellness monitoring using UWB radar |
| US10149617B2 (en) | 2013-03-15 | 2018-12-11 | i4c Innovations Inc. | Multiple sensors for monitoring health and wellness of an animal |
| US20140267299A1 (en) * | 2013-03-15 | 2014-09-18 | Intersections, Inc. | Veterinarian User Interface for Monitoring Health and Wellness of an Animal |
| US20160029946A1 (en) * | 2013-03-15 | 2016-02-04 | Adam J. Simon | Wavelet analysis in neuro diagnostics |
| CN103405224B (en) * | 2013-08-22 | 2015-01-07 | 乔金花 | Physiological index detection system for evaluating psychological neural activity |
| US10426365B1 (en) * | 2013-08-30 | 2019-10-01 | Keshab K Parhi | Method and apparatus for prediction and detection of seizure activity |
| WO2016057553A1 (en) | 2014-10-07 | 2016-04-14 | Masimo Corporation | Modular physiological sensors |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11406316B2 (en) * | 2018-02-14 | 2022-08-09 | Cerenion Oy | Apparatus and method for electroencephalographic measurement |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| KR102233341B1 (en) * | 2018-09-17 | 2021-03-29 | 인제대학교 산학협력단 | Method for predicting a suicidal behavior in major depressive disorder based on frontal alpha asymmetry and frontal activity |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4533346A (en) | 1979-06-26 | 1985-08-06 | Pharmacontrol Corporation | System for automatic feedback-controlled administration of drugs |
| US4407299A (en) * | 1981-05-15 | 1983-10-04 | The Children's Medical Center Corporation | Brain electrical activity mapping |
| US4862359A (en) | 1984-08-31 | 1989-08-29 | Bio-Logic Systems Corporation | Topographical mapping of brain functionality from neuropsychological test results |
| US4736751A (en) | 1986-12-16 | 1988-04-12 | Eeg Systems Laboratory | Brain wave source network location scanning method and system |
| US4907597A (en) | 1987-10-09 | 1990-03-13 | Biometrak Corporation | Cerebral biopotential analysis system and method |
| US5010891A (en) | 1987-10-09 | 1991-04-30 | Biometrak Corporation | Cerebral biopotential analysis system and method |
| US5083571A (en) * | 1988-04-18 | 1992-01-28 | New York University | Use of brain electrophysiological quantitative data to classify and subtype an individual into diagnostic categories by discriminant and cluster analysis |
| US5568816A (en) | 1990-09-07 | 1996-10-29 | Sam Technology, Inc. | EEG deblurring method and system for improved spatial detail |
| US5331970A (en) | 1990-09-07 | 1994-07-26 | Sam Technology, Inc. | EEG spatial enhancement method and system |
| US5119816A (en) | 1990-09-07 | 1992-06-09 | Sam Technology, Inc. | EEG spatial placement and enhancement method |
| US5299569A (en) | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
| US5269315A (en) | 1991-08-16 | 1993-12-14 | The Regents Of The University Of California | Determining the nature of brain lesions by electroencephalography |
| US5458117A (en) | 1991-10-25 | 1995-10-17 | Aspect Medical Systems, Inc. | Cerebral biopotential analysis system and method |
| US5320109A (en) | 1991-10-25 | 1994-06-14 | Aspect Medical Systems, Inc. | Cerebral biopotential analysis system and method |
| US5230346A (en) | 1992-02-04 | 1993-07-27 | The Regents Of The University Of California | Diagnosing brain conditions by quantitative electroencephalography |
| US5311876A (en) | 1992-11-18 | 1994-05-17 | The Johns Hopkins University | Automatic detection of seizures using electroencephalographic signals |
| US5617872A (en) * | 1994-07-25 | 1997-04-08 | Beth Israel Hospitcal Assoc. Inc. | Hypersensitive constriction velocity method for diagnosing Alzheimer's disease in a living human |
| US6425852B1 (en) | 1994-11-28 | 2002-07-30 | Emory University | Apparatus and method for transcranial magnetic brain stimulation, including the treatment of depression and the localization and characterization of speech arrest |
| US6463328B1 (en) | 1996-02-02 | 2002-10-08 | Michael Sasha John | Adaptive brain stimulation method and system |
| US6066163A (en) | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
| US5996022A (en) | 1996-06-03 | 1999-11-30 | Webtv Networks, Inc. | Transcoding data in a proxy computer prior to transmitting the audio data to a client |
| EP0828225A1 (en) | 1996-09-04 | 1998-03-11 | Siemens Aktiengesellschaft | Process and means for analysing EEG data |
| US5871517A (en) | 1997-01-15 | 1999-02-16 | Somatics, Inc. | Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment |
| US6128537A (en) | 1997-05-01 | 2000-10-03 | Medtronic, Inc | Techniques for treating anxiety by brain stimulation and drug infusion |
| DE19725214C1 (en) | 1997-06-15 | 1998-11-19 | Mario Dr Siebler | Brain electricity measurement analyser |
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| US6459936B2 (en) | 1997-10-27 | 2002-10-01 | Neuropace, Inc. | Methods for responsively treating neurological disorders |
| US6205359B1 (en) | 1998-10-26 | 2001-03-20 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
| US6539263B1 (en) | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
| US6304775B1 (en) | 1999-09-22 | 2001-10-16 | Leonidas D. Iasemidis | Seizure warning and prediction |
| JP4136273B2 (en) | 2000-05-24 | 2008-08-20 | パイオニア株式会社 | Aberration correction unit, optical pickup device and recording / reproducing device |
| WO2001097906A2 (en) | 2000-06-20 | 2001-12-27 | Advanced Bionics Corporation | Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
| EP2159723A1 (en) * | 2001-07-11 | 2010-03-03 | CNS Response, Inc. | Method for remote diagnosis and treatment using electroencephalografy |
| US6622047B2 (en) | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation |
| EP1460933B1 (en) | 2002-01-04 | 2008-12-17 | Aspect Medical Systems, Inc. | System and method of assessment of mood disorders using eeg |
| US7283861B2 (en) | 2002-04-30 | 2007-10-16 | Alexander Bystritsky | Methods for modifying electrical currents in neuronal circuits |
| US7706871B2 (en) * | 2003-05-06 | 2010-04-27 | Nellcor Puritan Bennett Llc | System and method of prediction of response to neurological treatment using the electroencephalogram |
| BRPI0410296A (en) | 2003-05-06 | 2006-05-16 | Aspect Medical Systems Inc | system and method for determining the efficacy of treatment of neurological disorders using electroencephalogram |
| US7206632B2 (en) * | 2003-10-02 | 2007-04-17 | Medtronic, Inc. | Patient sensory response evaluation for neuromodulation efficacy rating |
-
2006
- 2006-01-12 WO PCT/US2006/001059 patent/WO2006076478A2/en active Application Filing
- 2006-01-12 EP EP06718167A patent/EP1856643A1/en not_active Ceased
- 2006-01-12 US US11/330,593 patent/US8005534B2/en active Active
- 2006-01-12 AU AU2006204963A patent/AU2006204963B2/en not_active Ceased
- 2006-01-12 CN CNA2006800020780A patent/CN101529429A/en active Pending
- 2006-01-12 MX MX2007008439A patent/MX2007008439A/en active IP Right Grant
- 2006-01-12 BR BRPI0606306-3A patent/BRPI0606306A2/en not_active Application Discontinuation
- 2006-01-12 JP JP2007550586A patent/JP2008526388A/en active Pending
- 2006-01-12 CA CA2594456A patent/CA2594456C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8005534B2 (en) | 2011-08-23 |
| US20060167370A1 (en) | 2006-07-27 |
| AU2006204963B2 (en) | 2011-12-01 |
| MX2007008439A (en) | 2007-09-21 |
| AU2006204963A1 (en) | 2006-07-20 |
| EP1856643A1 (en) | 2007-11-21 |
| CN101529429A (en) | 2009-09-09 |
| JP2008526388A (en) | 2008-07-24 |
| BRPI0606306A2 (en) | 2009-06-16 |
| WO2006076478A2 (en) | 2006-07-20 |
| CA2594456A1 (en) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2594456C (en) | System and method for prediction of adverse events during treatment of psychological and neurological disorders | |
| Golonka et al. | Psychophysiological characteristics of burnout syndrome: Resting-state EEG analysis | |
| CA2472156C (en) | System and method of assessment of neurological conditions using eeg bispectrum | |
| Bachmann et al. | Single channel EEG analysis for detection of depression | |
| Cassani et al. | Towards automated electroencephalography-based Alzheimer’s disease diagnosis using portable low-density devices | |
| Kar et al. | EEG signal analysis for the assessment and quantification of driver’s fatigue | |
| Schmidt et al. | Index of alpha/theta ratio of the electroencephalogram: a new marker for Alzheimer’s disease | |
| Ginter Jr et al. | Phase and amplitude analysis in time–frequency space—application to voluntary finger movement | |
| Islam et al. | EEG mobility artifact removal for ambulatory epileptic seizure prediction applications | |
| JP2005514096A5 (en) | ||
| Gruszczyńska et al. | Epilepsy identification based on EEG signal using RQA method | |
| Höller et al. | Reliability of EEG measures of interaction: a paradigm shift is needed to fight the reproducibility crisis | |
| Yadav et al. | Morphology-based automatic seizure detector for intracerebral EEG recordings | |
| Zhao et al. | A study on EEG feature extraction and classification in autistic children based on singular spectrum analysis method | |
| McMackin et al. | Sustained attention to response task-related beta oscillations relate to performance and provide a functional biomarker in ALS | |
| Sharifi et al. | Directionality of corticomuscular coupling in essential tremor and cortical myoclonic tremor | |
| Qi | Algorithms benchmarking for removing EOG artifacts in brain computer interface | |
| Sharma et al. | Scalp electroencephalography (sEEG) based advanced prediction of epileptic seizure time and identification of epileptogenic region | |
| Windhager et al. | Are high frequency oscillations in scalp EEG related to age? | |
| Ieracitano et al. | Investigating the brain connectivity evolution in AD and MCI patients through the EEG signals’ wavelet coherence | |
| Qi | Evaluating algorithms of removing EOG artifacts with experimental data in brain computer interface | |
| Mohammed et al. | Penalized functional connectivity maps for patients with focal epilepsy | |
| Romanov et al. | Potential of a wavelet synchronization method for assessing the long-latency components of auditory evoked potentials in healthy humans | |
| Han et al. | Features and futures: seizure detection in partial epilepsies | |
| KR20230173439A (en) | Methods for predicting delirium occurrence and devices using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190114 |